Tag
This review examines the clinical relevance of a ≥30% decrease in VCTE-derived liver stiffness in predicting fibrosis regression in MASH, highlighting modest predictive accuracy and the need for improved biomarkers.
This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.
This prospective study confirms that liver stiffness measurement (LSM) by Fibroscan® effectively predicts transplant-free survival in primary sclerosing cholangitis (PSC), highlighting both static and dynamic assessments as powerful risk st
This prospective study confirms that liver stiffness measurements by Fibroscan® strongly predict transplant-free survival in primary sclerosing cholangitis patients, validating both static values and dynamic changes as vital prognostic mark
This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in bio
In primary biliary cholangitis, liver stiffness measurement (LSM) outperforms biochemical response in predicting first hepatic decompensation, emphasizing LSM’s pivotal role in clinical risk stratification despite frequent discordance
